Inclusion Criteria

- INCLUSION CRITERIA:

- Diagnosis of LAM either by tissue biopsy, evidence of lung and other organ
involvement (renal angiomyolipomas, chylous effusions, lymphangioleiomyomas), high
serum levels of vascular endothelial growth factor D (VGEF-D)(1) or a diagnosis of
TSC associated with cystic lung lesions.

- Age 18 years or over

- Evidence of airflow obstruction: FEV1/VC ratio < fifth percentile of predicted
normal and an FEV(1) < 80% predicted of the normal values.

EXCLUSION CRITERIA:

Subjects will be excluded from the study if they meet one or more of the following
criteria:

- History of hypersensitivity to albuterol or any of its components.

- Moderate or large pleural effusions

- History of seizures

- Inability to withhold bronchodilators for 24 hours

- Cognitive Impairment

- Age less than 18 years

- Male sex

- Status-post lung or kidney transplantation

- Pregnant or breast feeding (women of childbearing potential will undergo a blood or
urine pregnancy test under Protocol 95-H-0186).

- Treatment with monoaminoxidase inhibitors, tricyclic antidepressants or
Beta-adrenergic receptor antagonists or long acting anticholinergic bronchodilators
who are unable to be discontinued for at least seven days before enrollment.

- Patients with URI, uncontrolled hyperthyroidism or severe gastro-esophageal reflux.
Major systemic diseases (i.e., malignancy; myocardial infarction or unstable angina;
type 1 diabetes, severe hypertension; liver cirrhosis).